SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Robert P. Perrillo, Robert Gish, Yngve T. Falck-Ytter, American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy, Gastroenterology, 2015, 148, 1, 221

    CrossRef

  2. 2
    Kiran Motaparthi, Vladimir Stanisic, Abby S. Van Voorhees, Mark G. Lebwohl, Sylvia Hsu, From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti–tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis, Journal of the American Academy of Dermatology, 2014, 70, 1, 178

    CrossRef

  3. 3
    Fabrizio Cantini, Stefania Boccia, Delia Goletti, Florenzo Iannone, Emanuele Leoncini, Nikola Panic, Francesca Prignano, Giovanni Battista Gaeta, HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis, International Journal of Rheumatology, 2014, 2014, 1

    CrossRef

  4. 4
    Filomena Morisco, Maria Guarino, Serena La Bella, Luisa Di Costanzo, Nicola Caporaso, Fabio Ayala, Nicola Balato, Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis, BMC Gastroenterology, 2014, 14, 1

    CrossRef

  5. 5
    Issam R. Hamadah, Ali A. Al Raddadi, Khalid A. Bahamdan, Mohammad I. Fatani, Ali Alnahdi, Abdullah M. Al Rakban, Abdullah Alkhalifah, Ali Al Ameer, Yasir H. Shaikh, Ayman M. Elgendi, Abdulrahman Y. Al Zoman, Khalid A. Alafif, Saudi practical guidelines on biologic treatment of psoriasis, Journal of Dermatological Treatment, 2014, 1

    CrossRef

  6. 6
    Daniel Butler, Faranak Kamangar, Ethan Levin, John Koo, Anne Chang, Moderate to Severe Psoriasis, Fourth Edition, 2014,

    CrossRef

  7. 7
    L. Puig, J.M. Carrascosa, G. Carretero, P. de la Cueva, R.F. Lafuente-Urrez, I. Belinchón, M. Sánchez-Regaña, M. García-Bustínduy, M. Ribera, M. Alsina, C. Ferrándiz, E. Fonseca, V. García-Patos, E. Herrera, J.L. López Estebaranz, S.E. Marrón, J.C. Moreno, J. Notario, R. Rivera, C. Rodriguez-Cerdeira, A. Romero, R. Ruiz-Villaverde, R. Taberner, D. Vidal, Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento, Actas Dermo-Sifiliográficas, 2013, 104, 8, 694

    CrossRef

  8. 8
    Mariano Ara, Esteban Daudén, Etanercept for the treatment of psoriasis, Expert Review of Dermatology, 2013, 8, 4, 357

    CrossRef

  9. 9
    B. Guillot, Quoi de neuf en thérapeutique dermatologique ?, Annales de Dermatologie et de Vénéréologie, 2013, 140, S293

    CrossRef

  10. 10
    L. Puig, J.M. Carrascosa, G. Carretero, P. de la Cueva, R.F. Lafuente-Urrez, I. Belinchón, M. Sánchez-Regaña, M. García-Bustínduy, M. Ribera, M. Alsina, C. Ferrándiz, E. Fonseca, V. García-Patos, E. Herrera, J.L. López-Estebaranz, S.E. Marrón, J.C. Moreno, J. Notario, R. Rivera, C. Rodriguez-Cerdeira, A. Romero, R. Ruiz-Villaverde, R. Taberner, D. Vidal, Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment, Actas Dermo-Sifiliográficas (English Edition), 2013, 104, 8, 694

    CrossRef

  11. 11
    H.-Y. Chiu, C.-H. Chen, M.-S. Wu, Y.-P. Cheng, T.-F. Tsai, The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C, British Journal of Dermatology, 2013, 169, 6
  12. 12
    R.B. Warren, A. Al-Ri Fai, Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C, British Journal of Dermatology, 2013, 168, 3